Segall Bryant & Hamill, LLC Pacira Bio Sciences, Inc. Transaction History

Segall Bryant & Hamill, LLC

$7.16 Billion
Q3 2024

A detailed history of Segall Bryant & Hamill, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 32,061 shares of PCRX stock, worth $533,495. This represents 0.01% of its overall portfolio holdings.

Number of Shares

32,061

Holding current value

$533,495

% of portfolio

0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$11.7 - $28.46 $375,113 - $912,456	32,061 New	32,061 $482,000
Q3 2023 Nov 09, 2023	BUY	$30.68 - $40.09 $1.33 Million - $1.74 Million	43,481 Added 46.04%	137,925 $4.23 Million
Q2 2023 Aug 11, 2023	BUY	$36.12 - $47.5 $14,339 - $18,857	397 Added 0.42%	94,444 $3.78 Million
Q1 2023 May 15, 2023	BUY	$35.53 - $43.38 $41,392 - $50,537	1,165 Added 1.25%	94,047 $3.84 Million
Q4 2022 Feb 14, 2023	BUY	$38.19 - $57.45 $245,485 - $369,288	6,428 Added 7.44%	92,882 $3.59 Million
Q3 2022 Nov 14, 2022	BUY	$51.24 - $58.89 $87,671 - $100,760	1,711 Added 2.02%	86,454 $4.6 Million
Q2 2022 Aug 15, 2022	BUY	$51.49 - $81.64 $1.29 Million - $2.05 Million	25,078 Added 42.03%	84,743 $4.94 Million
Q1 2022 May 13, 2022	BUY	$60.03 - $76.49 $8,944 - $11,397	149 Added 0.25%	59,665 $4.55 Million
Q4 2021 Feb 14, 2022	BUY	$47.97 - $62.21 $132,972 - $172,446	2,772 Added 4.89%	59,516 $3.58 Million
Q3 2021 Nov 03, 2021	SELL	$54.64 - $61.3 $245,333 - $275,237	-4,490 Reduced 7.33%	56,744 $3.18 Million
Q2 2021 Aug 12, 2021	BUY	$59.18 - $69.99 $161,087 - $190,512	2,722 Added 4.65%	61,234 $3.72 Million
Q1 2021 May 13, 2021	SELL	$59.31 - $78.82 $15,361 - $20,414	-259 Reduced 0.44%	58,512 $4.1 Million
Q4 2020 Feb 12, 2021	SELL	$50.47 - $66.26 $49,309 - $64,736	-977 Reduced 1.64%	58,771 $3.52 Million
Q3 2020 Nov 13, 2020	BUY	$51.97 - $63.0 $2.03 Million - $2.46 Million	39,018 Added 188.22%	59,748 $3.59 Million
Q2 2020 Aug 14, 2020	BUY	$30.8 - $52.47 $13,890 - $23,663	451 Added 2.22%	20,730 $1.09 Million
Q1 2020 May 14, 2020	SELL	$28.4 - $50.7 $41,009 - $73,210	-1,444 Reduced 6.65%	20,279 $679,000
Q4 2019 Feb 11, 2020	SELL	$36.31 - $46.83 $42,773 - $55,165	-1,178 Reduced 5.14%	21,723 $984,000
Q3 2019 Nov 12, 2019	BUY	$35.66 - $44.99 $13,265 - $16,736	372 Added 1.65%	22,901 $871,000
Q2 2019 Aug 14, 2019	BUY	$36.57 - $47.97 $205,486 - $269,543	5,619 Added 33.23%	22,529 $0
Q1 2019 May 15, 2019	BUY	$36.47 - $42.17 $15,791 - $18,259	433 Added 2.63%	16,910 $0
Q4 2018 Feb 15, 2019	SELL	$41.31 - $52.16 $5,866 - $7,406	-142 Reduced 0.85%	16,477 $708,000
Q3 2018 Nov 14, 2018	SELL	$32.85 - $52.0 $1,708 - $2,704	-52 Reduced 0.31%	16,619 $0
Q2 2018 Aug 08, 2018	BUY	$27.5 - $39.8 $458,452 - $663,505	16,671 New	16,671 $0

Others Institutions Holding PCRX

# of Institutions

264

Shares Held

50.6M

Call Options Held

429K

Put Options Held

391K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $763M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.

Account

Segall Bryant & Hamill, LLC Pacira Bio Sciences, Inc. Transaction History